FDA lets drug makers go digital-only on prescribing info—with paper backup.

What it does

This bill allows pharmaceutical manufacturers to provide prescribing information to doctors and pharmacists electronically instead of on paper, provided they offer the option to receive or request paper copies at no extra cost. The FDA must issue regulations within one year to implement this change and ensure healthcare professionals can still get paper versions if they want them, with a public workshop within two years to review how the digital format is working.

Why we flagged it

The bill is a straightforward amendment to FDA labeling rules, permitting digital-only prescribing information with paper-copy safeguards. It is not a carve-out or immunity grant, but a modernization of communication channels with built-in consumer/provider protections.

What the text implies

• Digital-only defaults may create accessibility barriers for prescribers in rural or under-resourced settings with unreliable internet or limited digital infrastructure, even though paper copies remain available on request.
• Manufacturers gain discretion over digital format, font, layout, and update frequency, potentially enabling subtle changes to prescribing information that are harder to track than formal label amendments.
• The bill does not specify data-retention requirements or version control for digital prescribing information, creating potential disputes over which version was current at the time of prescribing.
• No explicit requirement that digital prescribing information be interoperable with electronic health record (EHR) systems, meaning prescribers may still need to manually cross-reference or print despite digital availability.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill creates a modest efficiency gain for manufacturers and potentially faster information updates, but shifts the burden of maintaining paper-copy infrastructure onto manufacturers and introduces a risk that digital-only defaults could disadvantage prescribers without reliable digital access or those who prefer paper for safety-critical reference. The mandatory opt-in for paper and no-cost fulfillment mitigate but do not eliminate this risk.

Who stands to gain

• pharmaceutical manufacturers (reduced paper production and distribution costs)
• digital health platforms and EHR vendors (potential integration opportunities)
• pharmaceutical packaging and logistics providers (reduced physical labeling volume)

Named in the bill

FDA, HHS Secretary, pharmaceutical manufacturers, prescribers, dispensers, Federal Food, Drug, and Cosmetic Act

Where it stands

16 cosponsors: 8 Democrats, 8 Republicans.

• Jun 25, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jun 25, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

5 lobbying clients named this bill on 5 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $1,637,670 in lobbying spend. A filing names 10 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 78% of bills with at least one filing.

Diana Harshbarger, the sponsor, reported $727,520 in PAC receipts in the 2026 cycle. $10,500 of that came from 2 PACs tied to these lobbying clients.

• Astrazeneca Pharmaceuticals Lp — $670,000 on 1 filing
• Cencora, Inc. — $510,000 on 1 filing
• Viatris Inc — $360,000 on 1 filing
• Printing United Alliance — $50,000 on 1 filing
• Healthcare Institute of New Jersey — $47,670 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.